טוען...
TRAIL in cancer therapy: present and future challenges
Since its identification in 1995, TRAIL (TNF-Related Apoptosis Inducing Ligand) has sparked growing interest in oncology due to its reported ability to selectively trigger cancer cell death. Contrary to other members of the TNF superfamily, TRAIL administration in vivo is harmless. The relative abse...
שמור ב:
| Main Authors: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Informa Healthcare
2007
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2976473/ https://ncbi.nlm.nih.gov/pubmed/17907960 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14728222.11.10.1299 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|